Top Buy Stocks
Sign In
Invest in MDWD
$19.09
-0.340 (-1.75%)
At Close: Jun 20, 2025
MediWound Ltd. (MDWD) Q1 2025 Earnings Call Transcript
12:46pm, Wednesday, 21'st May 2025
MediWound Ltd. (NASDAQ:MDWD ) Q1 2025 Earnings Conference Call May 21, 2025 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Ofer Gonen - CEO Hani Luxenburg - CFO Barry Wolfenson - EVP of
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
09:11am, Wednesday, 21'st May 2025
MediWound (MDWD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.39 per share a year ago.
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Wednesday, 21'st May 2025
VALUE Phase III trial of EscharEx ® in venous leg ulcers advancing as planned NexoBrid ® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue o
MediWound Ltd.: Undervalued High-Growth Potential
10:34am, Friday, 16'th May 2025
I rate MediWound a buy due to strong revenue growth, a robust pipeline, and significant undervaluation with massive upside potential. NexoBrid's commercial success and orphan drug status drive revenue
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
07:30am, Tuesday, 13'th May 2025
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®'s superior clinical performance and comparable safety profile to SANTYL® Post hoc analysis published in the peer-
MediWound to Report First Quarter 2025 Financial Results
08:00am, Monday, 05'th May 2025
Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
08:00am, Monday, 28'th Apr 2025
Presentations at WHS and SAWC to highlight EscharEx's mechanism of action, preclinical advantages over SANTYL ® , and new data in treating VLUs and DFUs Findings reinforce the ongoing Phase III study
MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript
12:10pm, Wednesday, 19'th Mar 2025
MediWound Ltd. (NASDAQ:MDWD ) Q4 2024 Results Conference Call March 19, 2025 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chie
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
09:10am, Wednesday, 19'th Mar 2025
MediWound (MDWD) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.19 per share a year ago.
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
07:00am, Wednesday, 19'th Mar 2025
Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results
08:00am, Monday, 03'rd Mar 2025
YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its f
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
08:00am, Tuesday, 25'th Feb 2025
Findings in Burns Journal confirm NexoBrid's superiority over standard of care in pediatric patients with deep thermal burns NexoBrid is approved for pediatric use in the U.S., E.U. and Japan YAVNE, I
MediWound to Present at the 45th Annual TD Cowen Health Care Conference
08:00am, Monday, 24'th Feb 2025
YAVNE, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Office
MediWound to launch Phase III trial for venous leg ulcers
08:12am, Wednesday, 12'th Feb 2025
MediWound , an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers.
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
07:00am, Wednesday, 12'th Feb 2025
Phase III trial to assess the efficacy and safety of EscharEx ® for debridement and facilitation of active wound closure
